September 7, 2022
Medical cannabis and pharmaceutical cannabinoids – Policy 04-06, Part II, Application 6 and Addendum A
We added a new application and addendum under Policy 04-06 to address coverage for pharmaceutical cannabinoids and cannabis authorized for medical use. The policy reflects current medical evidence, advice and knowledge about the benefits and risks of pharmaceutical cannabinoids and cannabis for therapeutic use.
Policies and Information Manual last updated September 7, 2022.
Sign up for policy notifications to learn when a policy has been updated or posted for consultation.
Find out more about the Policy Consultation Advisory Group (PCAG) and their role in our policy development and consultation process.